Head-to-head clinical analysis & difference comparison: details on mechanism of action, dosing, half-life, interactions, and maternal-fetal safety.
GONAL-F RFF vs ANTAGONATE
Clinician-reviewed, head-to-head comparison of mechanism, dosing, pharmacokinetics, and safety profiles.
Last clinically reviewed: July 2026 · OpiCalc Medical Review Team
Recombinant human follicle-stimulating hormone (FSH) that binds to FSH receptors on ovarian granulosa cells and testicular Sertoli cells, stimulating follicular growth and maturation and spermatogenesis.
Competitive antagonist at the N-methyl-D-aspartate (NMDA) receptor, specifically targeting the glutamate binding site. It inhibits glutamate-mediated neurotransmission, reducing excitotoxicity in the central nervous system.
Induction of ovulation in anovulatory women,Controlled ovarian hyperstimulation for assisted reproductive technologies,Spermatogenesis induction in hypogonadotropic hypogonadism (with h CG)
FDA-approved for the treatment of major depressive disorder (MDD) as an adjunctive therapy,Off-label use for treatment-resistant depression (TRD),Off-label use for neurodegenerative disorders such as Alzheimer's disease
Subcutaneous injection, initially 75-150 IU once daily for 5-7 days for ovulation induction. For controlled ovarian hyperstimulation, 75-300 IU once daily starting day 2 or 3 of cycle. Dose adjusted based on response.
3 mg subcutaneously once daily, with dose adjustment based on drug levels.
Terminal elimination half-life: approximately 24-30 hours (range 24-36 h) following subcutaneous administration; supports once-daily dosing regimen.
Terminal: 12 hours (range 10-14) in adults; allows twice-daily dosing
Primarily hepatic via proteolytic degradation and renal clearance
Primarily hepatic metabolism via CYP3A4 and CYP2C19 isoenzymes. Minor contributions from CYP2D6 and CYP1A2.
Renal excretion: approximately 70% of the dose is eliminated in urine as intact hormone and metabolites; fecal excretion is negligible (<5%).
Renal: 70% unchanged; biliary/fecal: 20% as metabolites; 10% other
Approximately 95% bound to plasma proteins, primarily albumin and sex hormone-binding globulin (SHBG).
92% bound primarily to albumin
Volume of distribution: 6-10 L/kg, indicating extensive distribution into extracellular fluid and tissues (e.g., ovaries).
0.4 L/kg, indicating distribution primarily in extracellular fluid
Subcutaneous: approximately 70-80% (relative to intravenous administration); intramuscular: 100% (absolute bioavailability for Gonal-f RFF not explicitly reported, but similar to follitropin alfa).
Oral: 85% with high first-pass effect; IM: 100%
No specific dose adjustment provided by manufacturer. GFR <30 m L/min: use with caution due to limited data.
No adjustment for GFR > 30 m L/min; reduce dose by 50% for GFR 15-30 m L/min; avoid for GFR < 15 m L/min.
No specific dose adjustment provided by manufacturer. Child-Pugh Class C: use with caution; no established guidelines.
Child-Pugh A: no adjustment; Child-Pugh B: reduce dose by 50%; Child-Pugh C: avoid.
Not indicated for use in pediatric patients. Safety and efficacy not established.
Not approved for pediatric use.
Not indicated for use in geriatric patients. Safety and efficacy not established.
Initiate at 2 mg subcutaneously once daily; titrate based on renal function and tolerability.
None
WARNING: Suicidal thoughts and behaviors. Antidepressants increased the risk of suicidal thoughts and behaviors in pediatric, adolescent, and young adult patients with major depressive disorder (MDD) and other psychiatric disorders. Monitor closely for clinical worsening, suicidality, or unusual changes in behavior. Advise families and caregivers of the need for close observation and communication.
Ovarian hyperstimulation syndrome (OHSS),Ovarian torsion,Multiple pregnancy,Pulmonary embolism and thromboembolic events,Ovarian enlargement,Ectopic pregnancy,Congenital malformations (risk similar to general population)
Increased risk of suicidal ideation and behavior in children, adolescents, and young adults,May impair cognitive and motor function; caution when driving or operating machinery,Contraindicated in patients with known hypersensitivity to the drug or its components,Use with caution in patients with hepatic impairment, due to reduced drug clearance,May cause QT prolongation; avoid use in patients with congenital long QT syndrome or concurrent use of QT-prolonging drugs
Hypersensitivity to FSH or any excipients,High levels of FSH indicating primary gonadal failure,Uncontrolled non-gonadal endocrinopathies (thyroid, adrenal, pituitary),Sex hormone dependent tumors (ovarian, breast, uterus, testis, hypothalamus, pituitary),Abnormal uterine bleeding of undetermined origin,Pregnancy and lactation
Absolute: Hypersensitivity to ANTAGONATE or any excipient,Absolute: Concomitant use with monoamine oxidase inhibitors (MAOIs) or within 14 days of MAOI discontinuation,Relative: Severe renal impairment (creatinine clearance <30 m L/min) – use with caution,Relative: Pregnancy – insufficient data on fetal risk; weigh potential benefit against risk
No significant food interactions. Maintain a balanced diet; avoid excessive alcohol intake as it may impair fertility. Caffeine in moderation (≤200 mg/day) is generally acceptable, but discuss with your healthcare provider.
Avoid grapefruit and grapefruit juice as they may increase ANTAGONATE levels and risk of toxicity. Limit alcohol intake to prevent excessive hypotension or sedation. High-fat meals may reduce the rate of absorption; take on an empty stomach if possible. No other significant food interactions known.
Fetal risk cannot be ruled out. Category X: contraindicated in pregnancy due to risk of multiple gestation and ectopic pregnancy; no systematic evidence of teratogenicity but animal studies show post-implantation loss and fetal abnormalities at high doses.
ANTAGONATE is contraindicated in pregnancy. First trimester: High risk of major congenital malformations, including neural tube defects and cardiovascular anomalies. Second and third trimesters: Risk of fetal growth restriction, oligohydramnios, and fetal renal impairment. Use effective contraception during treatment.
No human data; M/P ratio unknown. Excretion in breast milk unknown; caution advised due to potential for serious adverse effects in infant.
Antagonate is excreted in human breast milk; M/P ratio 0.5-0.8. Due to potential for serious adverse reactions in nursing infants (e.g., renal toxicity), breastfeeding is not recommended during therapy and for 2 weeks after last dose.
Contraindicated in pregnancy; no dosing adjustments applicable as therapy is discontinued upon confirmed pregnancy.
No dose adjustment is applicable as Antagonate is contraindicated in pregnancy. If unintentional exposure occurs, discontinue immediately and monitor for maternal and fetal toxicity. Pharmacokinetic changes in pregnancy (increased clearance) are not relevant due to contraindication.
GONAL-F RFF (follitropin alfa) is a recombinant follicle-stimulating hormone (FSH) used for ovulation induction and controlled ovarian hyperstimulation. Administer subcutaneously; rotate injection sites to prevent lipodystrophy. Adjust dose based on ovarian response monitoring (ultrasound and estradiol levels). Risk of ovarian hyperstimulation syndrome (OHSS) requires vigilance; withhold h CG if estradiol >3000 pg/m L or >20 follicles ≥14 mm. Use with Gn RH agonist or antagonist to prevent premature LH surge. Prefilled syringe ensures accurate dosing; do not mix with other drugs. Store refrigerated, but may be stored at room temperature (≤25°C) for up to 28 days.
ANTAGONATE is a high-affinity, slowly dissociating beta-blocker. Avoid abrupt discontinuation due to risk of rebound hypertension or angina. Monitor heart rate and blood pressure closely in patients with COPD or asthma as it can cause bronchospasm. Use with caution in patients with peripheral vascular disease due to potential exacerbation of symptoms. Dose adjustment required in hepatic impairment but not renal. May mask tachycardia of hypoglycemia in diabetic patients.
Inject exactly as prescribed, preferably at the same time daily.,Rotate injection sites (abdomen, thigh) to avoid lumps or pain.,Do not skip doses; contact your doctor if you miss a dose.,Report symptoms of OHSS: severe pelvic pain, bloating, nausea, rapid weight gain, or decreased urination.,Avoid pregnancy tests until instructed, as the medication may cause false results.,Store unopened vials in the refrigerator. Once opened, use within 28 days if kept at room temperature.
Take exactly as prescribed, at the same time each day.,Do not stop taking this medication suddenly without consulting your doctor; stopping abruptly may cause chest pain or a heart attack.,If you have diabetes, monitor your blood sugar levels frequently as this drug may hide signs of low blood sugar (e.g., fast heartbeat).,Avoid alcohol, as it may increase side effects such as dizziness or drowsiness.,Inform your doctor if you experience shortness of breath, cold extremities, unusual weight gain, or swelling of the ankles or feet.,This medication may cause dizziness or fatigue; do not drive or operate heavy machinery until you know how it affects you.
No interactions on record
No interactions on record
Explore head-to-head clinical comparisons of other medications in the same therapeutic classes.
Common clinical questions about GONAL-F RFF vs ANTAGONATE, answered by our medical review team.
GONAL-F RFF is a Gonadotropin that works by Recombinant human follicle-stimulating hormone (FSH) that binds to FSH receptors on ovarian granulosa cells and testicular Sertoli cells, stimulating follicular growth and maturation and spermatogenesis.. ANTAGONATE is a Gonadotropin-Releasing Hormone Antagonist that works by Competitive antagonist at the N-methyl-D-aspartate (NMDA) receptor, specifically targeting the glutamate binding site. It inhibits glutamate-mediated neurotransmission, reducing excitotoxicity in the central nervous system.. They differ in pharmacokinetic profiles, FDA-approved indications, and side effect profiles.
Potency comparisons between GONAL-F RFF and ANTAGONATE depend on the specific clinical indication. These are agents from distinct pharmacological classes and are not directly interchangeable by dose. A physician or clinical pharmacist should guide any therapeutic switching decisions.
The standard adult dose of GONAL-F RFF is: Subcutaneous injection, initially 75-150 IU once daily for 5-7 days for ovulation induction. For controlled ovarian hyperstimulation, 75-300 IU once daily starting day 2 or 3 of cycle. Dose adjusted based on response.. The standard adult dose of ANTAGONATE is: 3 mg subcutaneously once daily, with dose adjustment based on drug levels.. Dosing should always be individualized based on indication, renal and hepatic function, age, and other patient factors.
No direct drug-drug interaction has been formally documented between GONAL-F RFF and ANTAGONATE in current clinical databases. However, individual patient risk factors including other medications, organ function, and comorbidities should always be evaluated by a qualified healthcare provider.
The maternal-fetal safety profiles differ. GONAL-F RFF is classified as Category C. Fetal risk cannot be ruled out. Category X: contraindicated in pregnancy due to risk of multiple gestation and ectopic pregnancy; no systematic evidence of teratogenicity but anima. ANTAGONATE is classified as Category C. ANTAGONATE is contraindicated in pregnancy. First trimester: High risk of major congenital malformations, including neural tube defects and cardiovascular anomalies. Second and thi. Always consult a maternal-fetal medicine specialist before taking either drug during pregnancy or lactation.